Theralase Technologies Inc. V.TLT

Given time investors will connect the dots...

[wildbird1]

It is not easy for most peoples(including me) to understand the process of TLT cancer treatment.

Let's resume.
-TLT cancer treatment has a high CR ratio(complete Response) could easily be well over 70%
(70 % is huge).
-TLT cancer treatment has a very low toxicity.
-TLT cancer treatment has a memory response..meaning after the cancer treatment is completed, the patients own immune system start killing cancer cells on it's own.

The three above statements taken alone do not seem much, but taken together it does mean that TLT cancer treatment will be able to treat cancer patients with a weakened immune system, or patients that do not respond to Chemotherapy, or patients that do not respond to Radiation Therapy, and finally treat patients that do not respond to BCG treatment.
That is a lot's of patients.

And the most interesting fact is that TLT cancer treatment doesn't target a very specific cancer cells(like prostate cancer cells), no TLT cancer treatment will target any cancer cells from any cancer(Lung, Brain....).

Valuation...
Once TLT prove that its treatment can cure Prostate cancer, investors will connect the dots and will price the SP value on the many cancer TLT treatment will be able to cure.

The low SP is annoying for now, we just need a little more patience and we will be rewarded big time very soon.

[ScienceFirst]

As Prof. McFarland once mentioned, each molecule are designed to address specific indications instead of trying to target all indications.  That's how she's been successful in bringing TLD1433 close to bedside. So far, TLD1433 has not proven to be efficient enough for prostate or melanoma.  Other molecules, with more specific/different attributes are on their way (Osmium, etc ..

[gojotv!]

Where did you get this from, ScienceFirst? I was told by Dr. MacFarlane that the advantage of the Osmium compound is that it breaches the blood/brain barrier, making it the better choice for glioblastoma treatment She said nothing about the molecules being specific to cancer cell types. In fact, I believe that Dr. MacFarlane treated her own melanoma with the Ruthenium-based PDC. So, I'm

[ScienceFirst]

Gojotv ...  1) It's Dr. McFarland.  Not McFarlane! 2) It's impossible that she's been treated for her melanoma condition with a Ru pdc as NMIBC is the first Ru to be brought into human clinical trial. 3) I never mentioned anything about the blood/brain/barrier (BBB) in my previous post! 4) It is not an Osmium pdc that crosses the BBB but our own Rutherrin

[99942Apophis]

wildbird1 wrote It is not easy for most peoples(including me) to understand the process of TLT cancer treatment. Let's resume. -TLT cancer treatment has a high CR ratio(complete Response) could easily be well over 70% (70 % is huge). -TLT cancer treatment has a very low toxicity. -TLT cancer treatment has a memory response..meaning after the cancer treatment is completed, the patients own

[Oilminerdeluxe]

Will it be a Friday after the close release? As long as it is good...

[wildbird1]

99942Apophis you are absolutely correct it is Bladder cancer. Thank's for correcting me, and I agree with you many big  investors could already be looking into TLT. These big investors have research teams that can do very good DD and predict the end results of a cancer treatments trial way before most of us can. Most of these big buyers will not rush in unless they have solid CR (complete

[CancerSlayer]

Wildbird1 wrote: "99942Apophis you are absolutely correct it is Bladder cancer. Thank's for correcting me, and I agree with you many big  investors could already be looking into TLT. These big investors have research teams that can do very good DD and predict the end results of a cancer treatments trial way before most of us can. Most of these big buyers will not rush in unless they

[CancerSlayer]

  The versatile structural chemistry of this metallic compound gives it a big advantage over other conventional therapies (I.e. chemo, radiation, etc...) that have a single molecular target (I.e. DNA), which makes these therapies so toxic to our healthy cells.   A little structural tinkering of our compound (I.e. changing the ligand attached to the Ruthenium, Osmium, or other

[99942Apophis]

CancerSlayer wrote  As for the current sp activity, it is meaningless & should be ignored as it obviously doesn't accurately reflect where we currently stand with our CRs in this pivotal phase...upon which a determination for drug approval will be based. 100% agree CancerSlayer current Share Price has been manipulated keeping it at an insulting low price nowhere near it's true

[jicoop]

and I'll this one step further .. The three above statements taken alone do not seem much, but taken together it does mean that TLT cancer treatment will be able to treat cancer patients with a weakened immune system, or patients that do not respond to Chemotherapy, or patients that do not respond to Radiation Therapy, and finally treat patients that do not respond to BCG treatment. How

[floatinketucky]

Yes, expect to hear more on solid tumor destuction with xray activaton in the future.  They go together hand in hand.